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Abstract
Lysophosphatidic acid (LPA) influences many physiological processes, such as
brain and vascular development. It is associated with several diseases including ovarian
cancer, breast cancer, prostate cancer, colorectal cancer, hepatocellular carcinoma,
multiple myeloma atherosclerotic diseases, cardiovascular diseases, pulmonary
inflammatory diseases and renal diseases. LPA plasma and serum levels have been
reported to be important values in diagnosing ovarian cancer and other diseases. However,
the extraction and quantification of LPA in plasma are very challenging because of the
low physiological concentration and similar structures of LPA to other phospholipids.
Many previous studies have not described the separation of LPA from other
phospholipids, which may make analyses more challenging than necessary.
We developed an SPE extraction method for plasma LPA that can extract LPA at
high purity. We also developed an HPLC post-column fluorescence detection method that
allows the efficient quantification of LPA. These methods were used in a clinical study
for ovarian cancer diagnosis to help validate LPA as a biomarker of ovarian cancer.
Moreover, molecular imprinted polymers (MIPs) were designed and synthesized as
material for the improved extraction of LPA. Compared to the commercially available
materials, the MIP developed shows enhanced selectivity for LPA. The extraction was
overall relatively more efficient and less labor-intensive.
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Chapter 1

1.1

Introduction

Structure and formation of LPA
Lysophosphatidic acid (LPA) is a phospholipid that consists of a phosphate head

group, a glycerol backbone and an alkyl chain structure. LPA has many subspecies based
on differing length and saturation of the alkyl chain. The structures of five major LPA
species are shown in Figure 1.1.

Figure 1.1 Structures of lysophosphatidic acids (LPAs).

LPA can be produced by at least two distinct enzymatic mechanisms. The main
source is the hydrolysis of lysophosphatidylcholine (LPC) by lysophospholipase D (lysoPLD), such as autotaxin (ATX). It can also be generated from the hydrolysis of PA via
phospholipase A1 (PLA1) or phospholipase A2 (PLA2).
mechanisms using LPA 18:1 as an example.

1

1

Figure 1.2 shows the two

Figure 1.2 Two distinct enzymatic mechanisms of LPA generation.

As a bioactive phospholipid, LPA can activate specific cell-surface G proteincoupled receptors that initiate many cellular processes, such as cell proliferation
migration

4

and platelet aggregation

5,6

2 3

,

. LPA also influences many physiological

processes such as brain development 7, vascular development 8, wound healing and
pathological conditions, including autoimmune disorders and tumor metastasis. 9 10 11
1.2

LPA as a biomarker of ovarian cancer
There are more than 20,000 new cases of ovarian cancer in the US every year.

More than 60 % of all patients die from this disease. 12 The early stages of the disease are
2

difficult to diagnose because of a lack of specific symptoms. The majority of patients are
diagnosed with stage III or IV disease, while ca. 30% of are diagnosed at stage I or II. An
important determinant of ovarian cancer survival is the stage of the disease at diagnosis.
13

The five-year survival relative survival rates are more than 90% for stage I, while only

less than 10% for stage IV. (Figure 1.3)

Figure 1.3 Ovarian cancer five-year relative survival rates.

Currently, there is no accurate and effective screening test for the early detection
of ovarian cancer. Pelvic exam is a common way to diagnose ovarian cancer. However, it
only detects the disease occasionally and usually when the disease is advanced. The
combination of a thorough pelvic exam, an ultrasound and a blood test for the biomarker
CA125 are suggested, but are not proven completely effective yet.

3

In 1998, Xu et al. found that increased LPA levels in human plasma were related
to ovarian cancer. LPA as a biomarker showed advantages in early stage detection
compared to CA125, which was used as the conventional biomarker control for ovarian
cancer diagnosis. According to their results, 90% of the stage I patients have an elevated
level of LPA while only 20% have an elevated level of CA125.

14

Figure 1.4 shows the

percentage of patients that have elevated levels of LPA and CA125 in different stages.

Figure 1.4 Comparison of LPA and CA125 as biomarkers for ovarian cancer at different stages.

After this result was published, many other groups studied the correlation of LPA
and ovarian cancer and reported LPA as a perspective marker 15 16, 17 18, 19 although some
groups had different opinions 20. Liu et al. 21 reported that LPA promoted ovarian cancer
progression by inducing MMP-9 expression and MMP-9-catalyzed E-cadherin
ectodomain shedding.

4

1.3

LPA and other diseases
LPA influences many physiological processes, such as brain7 and vascular

development
breast cancer

8

and is involved in many diseases apart from ovarian cancer
22

, prostate cancer

multiple myeloma

26

23

, colorectal cancer

atherosclerotic diseases

24

14

, such as

, hepatocellular carcinoma

27 28

, cardiovascular diseases

29

25

,

, pulmonary

inflammatory diseases 30, renal diseases 31, 32.
1.4

Challenge of LPA analysis in human plasma
Quantification of LPA in plasma is very challenging because of its low

physiological concentration. The concentration of phospholipids in human plasma is >
2000 µM

33

. Among the several classes of phospholipids that are present in human

plasma, LPA represents a relatively very small fraction, and reported concentrations of
total LPA vary. A generally reported range is 1-5 µM 34. This makes it very challenging
for the selective isolation and enrichment of these analytes. Moreover, some studies
showed that not total LPA, but certain subspecies of LPA are the biomarkers of ovarian
cancer. 17 Thus, it is necessary to separate and quantify each individual LPA species.
Additionally, other phospholipids could interfere both the extraction and detection
because of their similar structures to LPA. For example, the lysophospholipids such as
lysophosphatidylethanolamine

(LPE),

lysophosphatidylcholine

(LPC)

and

lysophosphatidylserine (LPS) have similar structures to LPA, with only different head
groups. Phosphatidic acids (PA) have the same head group as LPA, but have an extra
alkyl chain than LPA.

Structures of representative lysophospholipids are shown in

Figures 1.5 and 1.6. Moreover, the concentrations of some of these phospholipids are
5

much higher than LPA in human plasma. For example, the concentration of LPC is
around 300 µM.35 It is not only difficult to quantify LPA in the presence of LPC, but it is
also challenging to separate them because of the similar properties.

Figure 1.5 Structure comparison of PA and LPA.

6

Figure 1.6 Structures of representative lysophospholipids.

7

Chapter 2

2.1

Extraction and HPLC post-column quantification of LPA in plasma

Introduction
HPLC post-column fluorescence probe-assisted methods have been reported for

phospholipids previously
commercially

available

36-38

. However, they had not found utility in LPA analyses. A

fluorescent

probe

4-(4-(dihexadecylamino)

styryl)-N-

methylpyridinium iodide (DiA) is used in this study as a post-column reagent for the
detection and quantification of LPA. Structure of DiA is shown in Figure 2.1 One may
separate and quantify six individual LPA subspecies at physiological levels in plasma
with a C-8 column in 15 minutes. In contrast to the currently used liquid
chromatography–mass spectrometry (LC-MS) methods, LPA levels obtained by optical
method are not susceptible to ionization-related issues.

To date, a number of separation and detection methods to determine LPA levels
have been developed. In 1998, Xu et al.

14

used a gas chromatography (GC) method to

quantify total levels of LPA in plasma. Chen et al.39 used capillary electrophoresis (CE)
to quantify individual LPAs with an indirect ultraviolet (UV) detection method. However,
to separate LPA from other lipids before detection, many of these early studies employed
two-dimensional thin layer chromatography (TLC).

14, 15, 39, 40

High performance liquid

chromatography (HPLC) has been used to separate LPA. Solid supports have included

[Wang, J. et al. Simple enrichment and analysis of plasma lysophosphatidic acids. Analyst 138,
6852-6859 (2013).] - Reproduced by permission of The Royal Society of Chemistry.

http://pubs.rsc.org/en/content/articlelanding/2013/an/c3an01168b#!divAbstract

8

normal phase (used in hydrophilic interaction chromatography), reversed phase (C8, C18)
and diol-bonded phases.
For example, Holland et al.41 used a diol-bonded phase to separate LPA from
other phospholipid classes with evaporative light-scattering detection (ELSD). This
avoids the 2-D TLC step; however, LPA recovery is 53.4% and there is no effort to
separate LPA subspecies. LC-MS has also been used to quantify LPAs.

3

More recently

liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the method
of choice.15,

42, 43

However, there are reports that LC-MS/MS methods currently have

some drawbacks. First, not all endogenous matrix components are efficiently separated
from the target analytes. This leads to matrix effects that hamper the efficiency and
reproducibility

of

the

ionization

process.44-47

Phospholipids,

especially

glycerophosphocholines and lysophosphatidylcholines, are cited as the major causes of
matrix effects due to their highly ionic character. This affects the electrospray MS source
by either suppressing or enhancing ionization. This cannot be compensated for by adding
internal standards, including isotopically labelled phospholipids. Wang et al.45
demonstrated that slight differences in retention times between the analyte and the
isotopically-labelled internal standard cause differences in ion suppression between the
two. In their study, the results vary up to 52% in peak areas from one plasma sample to
another because of matrix effects resulting in up to 18.9 % of variation in concentration.
Matrix effects may also result in retention time shifts, elevated baselines and divergent
calibration curves. Second, conversion of lysophosphatidylcholine (LPC) and
lysophosphatidylserine (LPS) to LPA occurs at the ion source of electrospray ionization
tandem mass spectrometry. Shan et al.48 found that unidentified compounds in plasma
9

produce the same parent-to-daughter ion transition as LPA in a direct flow injection
liquid

chromatography-electrospray

ionization-tandem

mass

spectrometry

(LC-

ESI/MS/MS) method and could reduce the accuracy of the analysis of LPA. Zhao et al.49
later reported that LPC and LPS lose their respective choline or serine moieties at ion
source to generate LPA-like signals.
In order to overcome the limitations described above, we propose a
straightforward method combining a modified Bligh and Dyer

50

procedure with a solid

phase extraction (SPE) protocol. This isolates plasma LPA effectively enough to permit
the rapid detection of each of the subspecies via a standard HPLC fluorescence detector.
HPLC post-column fluorescence probe-assisted methods have been reported for
phospholipids previously;
commercially

available

36-38

however, they had not found utility in LPA analyses. A

fluorescent

probe

4-(4-(dihexadecylamino)

styryl)-N-

methylpyridinium iodide (DiA) is used in this study as a post-column reagent for the
detection and quantification of LPA. One may separate and quantify six individual LPA
subspecies at physiological levels in plasma with a C8 column in 15 minutes. In contrast
to the currently used LC-MS methods, LPA levels obtained by optical method are not
susceptible to ionization-related issues.
2.2
2.2.1

Experimental
Materials
All

lysophosphatidic

acids

including

1-myristoyl-2-hydroxy-sn-glycero-3-

phosphate (LPA 14:0), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 16:0), 110

heptadecanoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 17:0), 1-stearoyl-2-hydroxy-snglycero-3-phosphate (LPA 18:0), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 18:1)
and 1-arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 20:4) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). 4-(4-(Dihexadecylamino) styryl)-Nmethylpyridinium iodide (DiA) was purchased from AnaSpec (Fremont, CA, USA).
HPLC grade MeOH was purchased from Fisher Scientific. Ultra pure water was obtained
from a Milli-Q™ system. Phosphoric acid and monosodium phosphate were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Waters OASIS™ HLB (3 cc, 60 mg, 30 μm)
SPE cartridges were purchased from Waters Corporation (Milford, MA, USA).
Lyophilized Human Plasma was purchased from Sigma-Aldrich. Human plasma was
collected by Lampire Biological Laboratories Inc., from female donors, processed to
obtain platelet-free plasma, and frozen at -80 ºC.
2.2.2

Instrumentation
Fluorescence measurements were performed on a Cary Eclipse™ fluorescence

spectrophotometer, and absorption spectra performed on a Cary 50™ UV-Vis
spectrophotometer (Agilent Technologies). The HPLC system consists of a 1525 binary
HPLC delivery system, a 2475 multi lambda fluorescence detector (Waters). A Luna™
C8 (50 × 2 mm, 3 μm) column connected to a guard cartridge with 2.0 to 3.0 mm internal
diameters (Phenomenex) was used for all the separations. The reagent is pumped by a
reagent manager (Waters). The DiA solution and the liquid eluting from the column are
merged through a metal mixing tee and delivered to the detector. The data is collected
and processed with the Empower™ software suite (Waters). In the LC-ESI/MS/MS
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control method, LPAs were separated in an Accela UPLC system (Thermo Fisher, San
Jose, CA) and detected via an LTQ-Orbitrap XL Discovery instrument (San Jose, CA,
USA), equipped with an ESI ion max source.
2.2.3

Extraction and LPA enrichment procedure for plasma samples
Human plasma (0.8 mL) is mixed with 4 mL MeOH: CHCl3 2:1, and vortexed at

2000 rpm for 30 s. The mixture is incubated at 4 ºC for 20 min, warmed to rt and
centrifuged at 2000 rpm for 10 min. The supernatant is decanted from the precipitated
proteins and extracted with 2 mL phosphate buffer saline (10 mM, pH 7.4) and vortexed
at 2000 rpm for 30 s. The aqueous phase containing the LPAs is washed two times with
1.33 mL CHCl3 to remove the remaining neutral lipids. The aqueous layer is acidified to
pH 2.0 with concentrated H3PO4 to protonate the LPAs to convert them to their neutral
form.51 An SPE cartridge is preconditioned with 6 mL MeOH, followed by 3 mL H2O.
The acidified LPAs solution is loaded onto the cartridge and rinsed with 3 mL H2O
followed by 1 mL CHCl3. The SPE cartridge is dried by applying an N2 stream, and
LPAs are eluted with 4 mL of MeOH. The solvent is evaporated and the residue is
reconstituted in 0.16 mL MeOH: H2O 9:1.
2.2.4

Fluorescence determination of linearity and dynamic range for DiA: LPA 18:0
model system
Stock solutions of varying concentrations (0–150 µM) of LPA (18:0) were

prepared in a mixture of MeOH–CHCl3 1:1. To avoid aggregation of the lipids, films of
each sample were prepared by evaporation under an Ar stream, and the films
12

reconstituted in MeOH. Choline chloride (final concentration 6.4 mM)

52

was added

before mixing with DiA (final concentration 2.67 µM) aqueous solution.
2.2.5

HPLC post-column procedure for plasma analysis
Samples (20 µL) are injected and eluted with a 16:5 mixture of MeOH-phosphate

buffer (50 mM, pH 2.5) through a Luna C-8 (50 × 2 mm, 3 µm) column equipped with a
guard column. The end of the column is connected to a mixing tee allowing contact with
the post-column reagent solution (DiA, 10 µM). The flow rate of the mobile phase is set
to 0.32 mL min-1 and 0.62 mL min-1 for the post-column reagent. The entire procedure is
performed at room temperature.
2.2.6

LC-ESI/MS/MS validation procedure for plasma analysis
Chromatography was performed on a Luna C-8 (50 × 2 mm, 3 µm) column at 40

ºC with an injection volume of 10 µL. The mobile phase MeOH–HCOOH (10 mM, pH
2.5) 9:1 was delivered at a flow rate of 0.4 mL min-1. Ions were created in negative ion
mode by setting the sprayer voltage at 3.0 kV and the capillary temperature at 300 ºC.
2.3
2.3.1

Results and discussion
Selection of the post-column reagent
Typically, fluorescent probes used for the post-column detection of phospholipids

rely on the formation of aggregated non-fluorescent π-stacked assemblies. These
assemblies are disrupted, upon interaction with phospholipids, thereby restoring probe
fluorescence. Examples of phosphoplipid-interacting probes include 2,5-bis-2-(5-tert13

butyl)benzoxazolylthiophene (BBOT), 1,6-diphenyl-1,3,5-hexatriene (DPH) and 4-(4dimethylaminostyryl)-1-hexadecylpyridinium (DSHP).

37 53-55 56

Structures of BBOT,

DPH and DSHP are shown in Figure They are mainly used for the detection and
quantification of triglycerides, ceramides, glycosphingolipids and phosphatidylcholines.
In our hands, we found that both BBOT and DPH did not produce usable fluorescence
emission enhancement in the presence of lysophosphatidic acids. Other fluorescent
probes with amphiphilic properties were evaluated. 10-N-Nonyl acridine orange (NAO)
has been used in the analysis of certain phospholipids such as cardiolipin (CL);

36 57, 58

however, it did not produce a useful spectral response in LPA-containing solutions. The
amphiphilic cyanine-type probe 4-(4-(dihexadecylamino)styryl)- N-methylpyridinium
iodide (DiA) afforded the most promising results for LPA detection. These results can be
explained considering the structural characteristics of BBOT and DPH, which are
essentially non-polar probes, while LPA (and PA) are amphiphilic charged molecules.
Better binding is expected to occur with DiA through electrostatic interactions between
the quaternary ammonium moiety and the phosphate group of LPA. Probe structures
including DiA, DSHP, BBOT, DPH and NAO are shown in Figure 2.1.
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Figure 2.1 Structures of probe candidates including DiA, DPH, DSHP, NAO and BBOT.
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Figure 2.2 Absorption spectra (top) and fluorescence spectra (bottom) of 3 μM aqueous solutions
of DiA alone (dashed lines) and in the presence of 10 μM LPA 18:0 (solid lines).
Excitation/emisson wavelengths: 470/590 nm.

An aqueous probe solution (3 µM) responds to the addition of 10 µM LPA 18:0
with a 40% increase at 445 nm in absorption. Importantly, the probe exhibits weak
fluorescence in the absence of LPA and a 700% increase in fluorescence emission upon
addition of 10 µM LPA. (Figure 2.2) It is notable that a relatively small increase in the
extinction coefficient of DiA upon addition of LPA produced a dramatic increase in the
16

fluorescence response. It is known that DiA exhibits minimal fluorescence in aqueous
solution, yet the fluorescence emission has been found to increase greatly when bound to
membrane environments.

59

It follows that LPA bound DiA would exhibit similar

increases in fluorescence.
2.3.2

Probe concentration and flow rate
Solutions of DiA with concentrations ranging from 3 to 20 µM were evaluated for

LPA screening. The 10 µM DiA solution exhibited the best signal-to-noise (S/N) ratio,
with a relatively low fluorescence background. The optimal reagent flow rate for postcolumn detection was found to be 0.62 mL min-1. Higher flow rates resulted in relatively
better signal to noise ratios, however, a trade-off was dilution of the sample. To best
prepare a DiA solution in H2O, we found that DiA should be pre-dissolved in a small
amount of acetone (1% of H2O volume).
2.3.3

Mobile phase composition, pH and effects of other additives
Common solvent mixtures (MeOH–H2O, MeCN–H2O) used for reversed-phase

chromatography did not enable resolution of the targeted individual LPA subspecies.
Subspecies separation was dependent on buffer pH and concentration. Of the buffer
systems evaluated, phosphate afforded optimal separation and peak shapes. Optimal
resolution was achieved using MeOH–50 mM phosphate buffer, pH 2.5 in a ratio 16/5.
The parameters characterizing the chromatographic system for optimal separation of
LPAs are reported in Table 2.1-2.3.
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Table 2.1 Effect of column length on the resolution (Rs) and theoretical plates (N) for the separation of LPAs.a

LPA 14:0

column length

N

(mm)

(RT, min)

100b

312

LPA 20:4

Rs

18

1280
(3.83)

Rs

(RT, min)
2.31

(4.44)
50c

N

LPA 16:0

192

1486
(4.72)

Rs

(RT, min)
1.35

(5.56)
4.40

N

LPA 18:1

1715

1917

Rs

(RT, min)
NA

(6.53)
3.52

N

LPA 17:0

NA

(5.44)

1748

Rs

(RT, min)
NA

(7.89)
4.30

N

LPA 18:0

2712

(RT, min)
7.74

(8.71)
2.57

(6.61)

a

3416

Discovery Bio wide pore (Supelco), C-8, 3 μm, 2.1 mm diameter. Flow rate: 0.20 mL/min.

c

Luna (Phenomenex), C-8, 3 μm, 2.0 mm diameter. Flow rate: 0.27 mL/min.

3001
(11.87)

10.04

(7.32)

LPA concentration: 80 μM; mobile phase: 4/1 MeOH/50 mM pH 3.0 phosphate buffer; injection volume: 5 μL.

b

N

4361
(10.50)

Table 2.2 Effect of pH on the resolution (Rs) and theoretical plates (N) for the separation of LPAs.a
LPA 14:0
pH

LPA 20:4

N

Rs

N

(RT, min)
3.0

996

1331

Rs

7.93

1302

(3.16)

Rs

3.14

1040

3.41

(4.85)

1862

Rs

4.22

1860

(5.61)

1625

Rs

N

(RT, min)
1.65

(6.92)
4.82

LPA 18:0

N

(RT, min)

(5.59)

2000

LPA 17:0

N

(RT, min)

(4.69)
9.71

LPA 18:1

N

(RT, min)

(3.01)
2.5

LPA 16:0

397

(RT, min)
5.66

(7.78)
2.56

(6.99)

1630

2176
(11.12)

7.57

(7.88)

1828
(11.21)

a

LPA concentration is 5 μM; column: Luna C-8 50 × 2.0 mm; mobile phase: 7/2 MeOH/50 mM phosphate buffer; flowrate: 0.27
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mL/min. Injection volume: 20 μL.

Table 2.3 Resolution (Rs) and theoretical plates (N) for the final optimal conditions. The column size is 50×2.0 mm.a
LPA 14:0
N

LPA 20:4
Rs

(RT, min)
848
(3.96)
a

N

LPA 16:0
Rs

(RT, min)
6.25

1149
(5.76)

N

LPA 18:1
Rs

(RT, min)
3.75

2531
(6.84)

N

LPA 17:0
Rs

(RT, min)
5.71

2105
(8.58)

N

LPA 18:0
Rs

(RT, min)
2.65

1278
(9.72)

N
(RT, min)

8.28

2635
(13.96)

LPA concentration is 10 μM; mobile phase: 16/5 MeOH/50 mM phosphate buffer; flowrate: 0.32 mL/min. Injection volume: 20 μL.

2.3.4

Separation conditions
Of the reversed phase columns evaluated, the best results were obtained with a

C-8 column with a particle size of 3 µm. A 100 × 2.1 mm column enabled separation of
all LPAs but caused excessive back-pressure, and limited optimization of the
composition/flow rate of mobile phase. A shorter 50 × 2 mm column enabled increased
flow rate affording sharper peaks and significantly reduced analysis time (~ 15 min). The
parameters characterizing the chromatographic system for optimal separation of LPAs are
reported in Table 2.1–2.3. Minimizing the length of the tubing between the HPLC
column and post-column mixing tee is also critical for maximizing peak-to-peak
resolution and limits of detection.
2.3.5

Detection parameters
Determination of the optimum excitation and emission wavelengths for the HPLC

fluorescence detection system were performed as follows. The 3-D scanning mode in a
Waters 2475 fluorescence detector allowed us to establish the optimal excitation and
emission wavelengths that resulted in the highest signals and best peak shapes based on
the wavelength dependence of the excitation source and PMT detector employed by the
Waters 2475 fluorescence detection system. The largest LPA induced fluorescence
emission enhancement was observed to be near 570 nm when run in emission scanning
mode with excitation at 470 nm chosen based upon the excitation spectra in Figure 2.2.
The detector gain was set to 100. Subsequently, the acquisition was set to excitation
scanning mode (330–530 nm) keeping the emission wavelength constant (570 nm)
20

allowing collection of an excitation spectrum. The peak excitation wavelength resulting
in the greatest fluorescence enhancement was determined to be 450 nm. Consistent with
Figure 2.2, the post-column fluorescence response to LPA was much greater than
absorption. Fixed excitation and emission wavelengths of 450 and 570 nm, respectively
were used in all analyses and presented in all subsequent chromatograms. Figure 2.3
shows a representative HPLC trace using the optimized conditions for the separation of
LPA 14:0, 16:0, 17:0, 18:0, 18:1 and 20:4.

Figure 2.3 HPLC trace of a LPA mixture (10 μM LPA 14:0, 16:0, 18:0, 18:1, 20:4 and 20 μM
LPA 17:0). Chromatographic conditions: column: Luna™ C8, 3 μm, 50 × 2.0 mm;
mobile phase: MeOH: phosphate buffer (50 mM, pH 2.5) 16:5; flow rate: 0.32 mL/min;
injection volume: 20 μL; sample concentration: 10 μM in MeOH: H2O 9:1; post-column
reagent: 10 μM DiA in H2O; reagent flow rate: 0.62 mL/min; excitation/emission
wavelengths: 450/570 nm.
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2.3.6

Linearity and dynamic range
In order to determine the linear response of DiA to the presence of LPA, an initial

evaluation using LPA (18:0) as a model compound was carried out using direct
fluorescence spectrophotometry. Emission spectra were collected upon excitation at 470
nm. As shown in Figure 2.4, the plot of maximum fluorescence emission vs.
concentration confirms a good linear relationship (R2 = 0.994) between the fluorescence
intensity and LPA (18:0) concentrations ranging from 1 to 16 μM.

Figure 2.4 Emission spectra and calibration curve (inset) of 2.67 μM DiA upon titration with
LPA (18:0).

Based on the above results, we anticipated that a similar linear response would be
obtained for the individual LPAs after reversed phase HPLC separation. After
22

optimization of separation and detection conditions as described above, mixtures of LPAs
with concentrations ranging from 0.5 – 40 μM were evaluated.
All LPAs showed a linear response in the 0.5 – 25 μM concentration range,
although LPA 14:0, LPA 18:0 and LPA 18:1 exhibit linearity up to 40 μM. LPA (17:0),
a non-natural LPA, was added to these mixtures as an internal standard for further
quantification.

Figure 2.5 shows calibration curves for the individual LPA species

evaluated in this study. Acceptable correlation factors (R2) were obtained for all LPA
subspecies. The limit of detection (LOD) for each was determined as the amount of
analyte that corresponds to three times the signal of the background noise. Data from
calibration curves are shown in Table 2.4.

Figure 2.5 Calibration curves of specific LPA subspecies obtained by HPLC-post column
fluorescence detection. The area ratio is the peak area of individual LPAs divided by the
peak area of the internal standard (LPA 17:0). Data points represent the average of 4
runs.
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Table 2.4 Data obtained from calibration curves for LPA species via the HPLC post-column method.

LPA species

R2
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Retention time

Linear range

LOD

(min)

(μM)

14:0

3.50

0-40

0.9962

0.147

20:4

5.56

0-25

0.9962

0.161

16:0

6.64

0-25

0.9963

0.173

18:1

8.35

0-40

0.9949

0.074

18:0

13.75

0-40

0.9943

0.272

(μM)

2.3.7

Quantification of LPAs in human plasma
Biological concentrations of phospholipids in human plasma are higher than 3

mM.
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Among the several classes of phospholipids that are present in human plasma,

LPAs represent a relatively very small fraction, and reported concentrations of total LPA
vary. A generally reported range is 1-5 μM.34 This imposes a challenge for the selective
isolation/enrichment of these analytes.

Solid phase extraction (SPE) is a common

method for the removal of potential interferences from biological samples and has been
used for the isolation and enrichment of the different classes of phospholipids.60-62
Typical SPE materials include normal phase (e.g. silica), reversed phase (C4, C8 or C18),
ionic exchange and hybrid solid supports. The SPE enrichment procedure developed
herein specifically for LPAs increases their concentration 5-fold. Several solid supports
were initially evaluated in control mixtures containing LPA 14:0, 16:0, 17:0, 18:0, 18:1
and 20:4.

Three different commercial reversed phase C8 SPE cartridges, including

Waters (Sep-pak™ Plus C-8, 200 mg, 37-55 μm), Supelco (Discovery™ DSC-8, 3 mL,
500 mg, 50 μm) and Waters (OASIS™ HLB 3 mL, 60 mg, 30 μm) were evaluated. The
OASIS™ HLB proved optimal in terms of LPA recoveries (93-103%). As part of the
method development, a liquid-liquid extraction prior to the SPE procedure was used to
aid in removing relatively abundant and potentially interfering phospholipids. Typical
procedures for lysophospholipids reported in the literature involve acidification of plasma
prior to a liquid-liquid extraction.15, 63 In our hands, this procedure gave very low LPA
recoveries. We determined that pH control was critical to achieve the selective removal
of interferences. At physiological pH, LPAs are negatively charged.51 Thus, performing
the liquid-liquid extraction at pH 7.4 removes neutral phospholipids (e.g. LPC, LPS, etc.).
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The best recoveries were obtained when samples were loaded onto the SPE cartridge at
pH 2.0. Selective elution of LPAs from the SPE cartridges was achieved using MeOH.
This removes relatively hydrophobic species (e.g. phosphatidic acids). Table 2.5 shows
the recoveries obtained for LPA control samples. In general, the recoveries are in the 7494% range. In addition, we evaluated the effect of other phospholipids that have been
identified to be present in human plasma and can result in potential false positives for
LPAs.

It is known that phospholipids are prone to either chemical or enzymatic

hydrolysis. Phosphatidic acids (PAs) can be hydrolyzed enzymatically during sample
storage, producing the corresponding LPAs, resulting in false positive LPA readings.
Due to the acidic conditions in which the LPA solid phase extraction is carried out, we
performed control experiments to investigate PA hydrolysis consisting in submitting PA
standards to the whole extraction procedure. The resulting chromatograms did not show
any signal within 1 hour, hence, none of PA 14:0, 16:0, 18:0 or 18:1 are hydrolyzed
under the conditions used for the SPE-based LPA enrichment reported herein.
Phosphatidylcholines (PCs) represent the major components of biological membranes
and are also prone to hydrolysis producing the corresponding LPCs or PAs. Evaluation of
the hydrolysis of PC in the same fashion as with PA resulted in the absence of any
hydrolysis product confirming that PC or its hydrolysis products do not interfere in our
sample protocol.
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Table 2.5 Recoveries of individual LPA species after SPE enrichment.

Measured by HPLC- post column (n = 3)
LPA species

Measured by LC- ESI/MS/MS (n =3)
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Recovery (%)

σ (%)

Recovery (%)

σ (%)

14:0

93.5

4.8

93.7

2.9

20:4

73.8

4.3

76.6

1.2

16:0

94.2

5.4

95.7

4.6

18:1

76.9

4.9

77.6

1.7

17:0

85.1

3.8

85.0

4.6

18:0

76.9

4.4

73.1

2.4

An LC/MS full scan in both negative and positive modes was also used to
determine the presence of non-LPA phospholipids in plasma to confirm the effectiveness
of the new sample preparation extraction steps. A control mixture of 22 phospholipids
was initially tested, and all lipids were detectable in negative and/or positive mode. Mass
spectra are shown in Figure 2.6-2.9. A plasma extract was tested using the same method.
Results were compared to the LIPID MAPS Structure Database (LMSD).64 No
potentially interfering lipids found in the database were detected in negative mode.
Limited amounts of LPC 16:0 were detected in positive mode. To further determine the
extent of the interference from LPC, an LC-ESI/MS/MS method was used to detect LPC
subspecies. The concentration was estimated to be 0.06, 0.01 and 0.05 μM for LPC 16:0,
LPC 18:0 and LPC 18:1 respectively. These concentrations represent less than 0.1 % of
the total LPCs in human plasma,35,

65

thus LPC interference is not significant in our

method.
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LPA 18:1
LPS 18:1

LPA 20:4
LPA 14:0

PA 14:0

LPA 16:0

LPA 17:0

PA 18:1
LPE 18:1

LPA 18:0

PS 16:0
LPE 16:0

PA 16:0

PE 18:1

Figure 2.6 Mass spectra of phospholipids mixture in negative mode

Figure 2.7 Mass spectra of phospholipids mixture in positive mode
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PS 18:1

Figure 2.8 Mass spectra of plasma extract in negative mode

Figure 2.9 Mass spectra of plasma extract in positive mode
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2.3.8

Method validation via LC-ESI/MS/MS
Mixtures of LPAs with concentrations ranging from 0.5 – 40 μM were evaluated

using the LC-ESI/MS/MS method. We found a linear response for all the LPAs
throughout this range. To compare to the new HPLC post-column method, we selected a
working concentration range of 0.5 – 25 μM. LPA (17:0) was also used as an internal
standard. Figure 2.10 shows calibration curves for the individual LPA species evaluated
with the LC-ESI/MS/MS method. Acceptable correlation factors (R2) were obtained for
all the LPAs (Table 2.5). The limit of detection (LOD) for each LPA species was
determined as the amount of analyte that corresponds to three times the signal of the
background noise.

Figure 2.10 Calibration curves of LPAs using the LC-ESI/MS/MS method. The area ratio is the
peak area of individual LPAs divided by the peak area of the internal standard (LPA
17:0).
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Table 2.6 Statistical values obtained for the individual LPA species in the LC-ESI/MS/MS
method (n = 3).
LPA species

R2

Retention time

Linear range

LOD

(min)

(μM)

14:0

6.30

0-40

0.9991

0.0067

20:4

7.55

0-40

0.9990

0.0099

16:0

8.29

0-40

0.9998

0.0123

18:1

9.10

0-40

0.9993

0.0066

18:0

11.22

0-40

0.9991

0.0156

(μM)

Native LPA concentrations were determined in blind human plasma samples from
five different donors using both the MS and the optical methods. In addition, to further
evaluate other potential matrix interferences, these plasma samples were also spiked with
0.5 μM of each LPA species. Data from the samples collected from all five donors is
presented in Table 2.7-2.11. In each experiment, 800 μL of human plasma was used. All
samples were prepared and analyzed in triplicate. Result shows that LPAs concentrations
determined by the LC-ESI/MS/MS and HPLC optical post-column techniques are in
close agreement. Experimental recoveries were mostly higher in the HPLC-post column
method. Representative HPLC traces are shown in Figure 2.11 and Figure 2.12.
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Table 2.7 Results for LPA analysis in human plasma (donor A) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods.
non-spiked (μM)

spiked with 0.5 µM LPA (μM)

average, σ

average, σ

Recovery (%)
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HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

LPA 14:0

0.90 (0.01)

0.92 (0.01)

1.31 (0.09)

1.33 (0.05)

82

82

LPA 20:4

0.63 (0.02)

0.64 (0.03)

1.09 (0.05)

1.06 (0.03)

94

84

LPA 16:0

0.76 (0.03)

0.74 (0.01)

1.19 (0.09)

1.19 (0.01)

86

90

LPA 18:1

0.68 (0.01)

0.65 (0.02)

1.18 (0.01)

1.10 (0.03)

98

90

LPA 18:0

0.56 (0.02)

0.60 (0.01)

1.06 (0.03)

1.05 (0.01)

100

88

Total LPA

3.5 3(0.03)

3.56 (0.02)

5.83 (0.22)

5.73 (0.11)

92

87

Table 2.8 Results for LPA analysis in human plasma (donor B) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods.
non-spiked (μM)

spiked with 0.5 µM LPA (μM)

average, σ

average, σ

Recovery (%)

34

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

LPA 14:0

0.97(0.03)

1.03(0.01)

1.43(0.04)

1.45(0.03)

94

82

LPA 20:4

0.98(0.01)

0.94(0.01)

1.41(0.02)

1.43(0.01)

86

100

LPA 16:0

0.96(0.02)

1.04(0.02)

1.45(0.03)

1.60(0.03)

98

112

LPA 18:1

1.05(0.00)

1.03(0.02)

1.47(0.02)

1.55(0.02)

84

102

LPA 18:0

0.99(0.01)

0.93(0.01)

1.56(0.04)

1.47(0.01)

114

110

Total LPA

4.96(0.04)

4.97(0.04)

7.33(0.01)

7.50(0.08)

95

101

Table 2.9 Results for LPA analysis in human plasma (donor C) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods.
non-spiked (μM)

spiked with 0.5 µM LPA (μM)

average, σ

average, σ

Recovery (%)
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HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

LPA 14:0

0.76(0.01)

0.68(0.02)

1.25(0.02)

1.21(0.04)

98

106

LPA 20:4

0.21(0.02)

0.27(0.02)

0.64(0.01)

0.67(0.05)

84

80

LPA 16:0

0.55(0.01)

0.42(0.04)

1.05(0.05)

0.97(0.04)

100

112

LPA 18:1

0.37(0.01)

0.32(0.01)

0.96(0.05)

0.79(0.06)

120

96

LPA 18:0

0.29(0.03)

0.23(0.01)

0.79(0.01)

0.79(0.02)

102

112

Total LPA

2.18(0.02)

1.91(0.09)

4.69(0.08)

4.44(0.12)

100

101

Table 2.10 Results for LPA analysis in human plasma (donor D) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods.
non-spiked (μM)

spiked with 0.5 µM LPA (μM)

average, σ

average, σ

Recovery (%)
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HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

LPA 14:0

0.24(0.00)

0.23(0.01)

0.65(0.02)

0.68(0.02)

82

92

LPA 20:4

0.26(0.01)

0.28(0.01)

0.67(0.01)

0.65(0.04)

82

74

LPA 16:0

0.45(0.03)

0.43(0.01)

0.88(0.02)

0.83(0.04)

88

80

LPA 18:1

0.30(0.02)

0.38(0.01)

0.87(0.02)

0.85(0.03)

114

94

LPA 18:0

0.33(0.02)

0.31(0.00)

0.85(0.02)

0.82(0.01)

104

102

Total LPA

1.57(0.03)

1.63(0.03)

3.91(0.03)

3.83(0.12)

94

88

Table 2.11 Results for LPA analysis in human plasma (donor E) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods.
non-spiked (μM)

spiked with 0.5 µM LPA (μM)

average, σ

average, σ

Recovery (%)
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HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

HPLC post-column

LC-ESI/MS/MS

LPA 14:0

0.17(0.00)

0.18(0.01)

0.61(0.02)

0.60(0.00)

86

84

LPA 20:4

0.20(0.02)

0.23(0.01)

0.75(0.01)

0.77(0.01)

110

110

LPA 16:0

0.29(0.00)

0.28(0.02)

0.71(0.00)

0.76(0.01)

84

96

LPA 18:1

0.53(0.01)

0.47(0.02)

0.97(0.02)

1.03(0.00)

90

112

LPA 18:0

0.33(0.00)

0.30(0.01)

0.84(0.01)

0.89(0.00)

102

118

Total LPA

1.52(0.02)

1.45(0.05)

3.88(0.04)

4.06(0.01)

94

104

Figure 2.11 Chromatograms of a mixture containing 10 µM of each LPA species and LPAs
isolated from human plasma (donor A) using the post-column detection method.
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Figure 2.12 LC-ESI/MS/MS traces of a 10 μM standard mixture of LPAs. Column: Luna™ C8
(50 × 2 mm, 3 μm) at 40 ºC. Injection volume: 10 μL. Mobile phase: 9:1
MeOH:aqueous HCOOH (pH 2.5) at a flow rate of 0.4 mL/min. Parent and daughter
ions were detected in the negative ion mode, sprayer voltage; 3.0 kV, capillary
temperature at 300 ºC.

2.4

Conclusion
The optimized method for isolation and enrichment of LPA subspecies over other

related phospholipids developed herein affords the five major LPAs (LPA 14:0, 16:0,
18:0, 18:1 and 20:4) with essentially no other potentially interfering phospholipids. Using
this enriched mixture during analysis can eliminate matrix related errors caused by the
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presence of other phospholipids which can potentially generate LPAs upon hydrolysis.
The HPLC separation of the individual LPA subspecies reported herein is relatively rapid
(15 min), and non-destructive optical detection simplifies the selection of detection
instrumentation. Optical detection was validated using ESI/MS/MS detection, for which
the optimized sample enrichment procedure reduced or completely eliminated ionization
suppression effects that have been reported to complicate the measurement.
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Chapter 3

3.1

Clinical study of LPA levels in ovarian cancer patients

Introduction

Xu et al. 66 first reported that LPA levels were elevated in ovarian cancer patients
and LPA may be a biomarker of ovarian cancer, especially for early stages. Many other
groups have reported clinical studies supporting LPA as a diagnostic biomarker of
ovarian cancer. 17, 67 For example, Sedlakova et al. 19, 68 found that LPA levels in ovarian
cancer patients plasma were elevated by ~140% thus LPA could be useful as diagnostic
marker for ovarian cancer.
However, Baker et al. 20 found that neither individual LPA species nor total LPA
levels in plasma of ovarian cancer patients was significantly different than a healthy
control group. More recently, Lu et al.

69

studied more than 600 patients including

healthy women and those with ovarian cancer. The results showed that measurement of
total LPA levels in serum was highly accurate and sensitive towards the diagnosis of
ovarian cancer. Even among studies that showed plasma LPA levels were elevated in
ovarian cancer patients, the total LPA concentrations reported varied widely, from 2.57 to
43.2 µM for ovarian cancer patients.

17, 19, 34, 66

To help understand this controversial

issue, we performed a clinical study of LPA levels in ovarian cancer patients using the
method developed by our group, which is described in Chapter 2, in collaboration with
Women and Infants Hospital of Brown University Medical School in Rhode Island.
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3.2

Experimental

A total of 183 patient plasma and serum blind samples, including both healthy and
ovarian cancer patients, were collected at the Women and Infants Hospital of Brown
University Medical School in Rhode Island. Five subspecies of LPA including LPA 14:0,
LPA 16:0, LPA 18:0, LPA 18:1 and LPA 20:4 were extracted, enriched with a liquidliquid extraction followed by a solid phase extraction method as described in Chapter 2.
The concentrations of each LPA subspecies were determined with the HPLC post-column
fluorescence detection method we developed. 70
3.3

Results and discussion
Plasma LPA levels in all patients ranges (n = 183): LPA 14:0 (0.109-2.609

µmol/L), LPA 20:4 (0-1.953 µmol/L), LPA 16:0 (0.229-9.497 µmol/L), LPA 18:1 (00.632 µmol/L), LPA 18:0 (0-2.466 µmol/L), total LPA (0.519- 13.925 µmol/L). Serum
LPA levels in all patients ranges (n = 183): LPA 14:0 (0-2.649 µmol/L), LPA 20:4 (03.156 µmol/L), LPA 16:0 (0-11.853 µmol/L), LPA 18:1 (0- 0.729 µmol/L), LPA 18:0 (02.543 µmol/L), total LPA (0-15.109 µmol/L).
We noticed most of the plasma and serum samples are yellow and white.
However, some samples showed different colors, such as orange and red. These colors
might be from the residual red blood cells from sample processing.
All samples were quantified in 3 runs or 2 runs depending on the sample volume.
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Plasma and serum concentrations of LPA species and total LPA of all patients are
shown in Figure 3.1-3.6. Statistical analysis of the data for determination of the relevance
of LPAs as an ovarian cancer biomarker is currently underway by collaborators.
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44
Figure 3.1 LPA 14:0 concentrations in plasma and serum samples of 183 patients.

45
Figure 3.2 LPA 20:4 concentrations in plasma and serum samples of 183 patients.

46
Figure 3.3 LPA 16:0 concentrations in plasma and serum samples of 183 patients.

47
Figure 3.4 LPA 18:1 concentrations in plasma and serum samples of 183 patients.

48
Figure 3.5 LPA 18:0 concentrations in plasma and serum samples of 183 patients.

49
Figure 3.6 Total LPA concentrations in plasma and serum samples of 183 patients.

Chapter 4

4.1

Molecular imprinted polymer synthesis and evaluation

Introduction
A wide variety of methods for LPA sample preparation have been developed.

Liquid-liquid extraction (LLE) is the most common methodology for LPA enrichment
from biological samples. The LLE method developed by Bligh and Dyer

50

has been

modified and used in many studies. These modified methods that require one or two steps
are easy and fast.

3 71 42 49

However, they can also be less than ideal because abundant

potential interferences, such as lysophosphotidyl choline (LPC), can be co-extracted with
LPA and affect LPA quantifications.
For example, Zhao et al. found that lysophosphatidylcholine (LPC) and
lysophosphatidylserine (LPS) artificially generate LPA signals in electrospray ionization
tandem mass spectrometry (ESI-MS/MS) at the ion source via loss of the head group.

72

This fact may highly effect the quantification, since the biological concentration of total
LPC is about 300 µM, which is two orders of magnitude higher than LPA (< 5 µM) in
healthy people.

67, 73

Meanwhile, phospholipids such as glycerophosphocholines and

lysophosphatidylcholines, can cause matrix effects that suppress or enhance MS
ionization and also shift HPLC retention times and elevate baselines.

44, 46, 74

These

factors can hamper the accuracy and reproducibility of the quantification of LPA in LCMS. Other quantification methods besides LC-MS may also be affected by the presence
of interfering phospholipids in LPA samples because of the structural similarities
between LPA and other phospholipids. For example, phosphatidic acid (PA) has the same
head group as LPA; lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS)
50

and LPC all have the same or similar length of alkyl chains as LPA. Thus, if the detection
is based on phosphate group binding or deaggregation of a binding group induced by the
alkyl chain of LPA, the phospholipids that co-extract with LPA would interfere. Thus,
removal of interferences is critical for an accurate quantification of LPA.
Our group has reported a method for LPA extraction and enrichment by using
LLE followed by a solid phase extraction (SPE)

70

. With that method, LPA could be

extracted with a high recovery and purity level. To improve the efficiency of the sample
preparation and reduce the labor intensity and operational difficulties caused by LLE, we
eliminated the LLE step by using a synthetic MIP as the stationary phase in SPE.
Compared to LLE, SPE has advantages including high recoveries without partition issues,
and it is less labor intensive and time consuming, and is potentially automatable.
Molecularly imprinted polymers (MIPs) are highly cross-linked polymers that can
be used as artificial receptors for specific molecules. 75-77 MIPs have been mostly used in
chromatography 78-80, electrophoresis
88

and catalysis

crystallization

89 90

95-98

81, 82

, solid phase extraction 83, chemical sensing 84-

. New applications of MIPs also include drug delivery

, synthetic antibodies

99, 100

and cell culturing

101-103

91 92 93 94

,

. To synthesize

MIPs, the template and functional monomers are bound covalently or non-covalently
before copolymerized with the presence of a high concentration of crosslinking
monomers. After the removal of the template, a polymer with cavities and binding sites is
formed and can be used to bind target molecules selectively. MIPs have many advantages
as a material for the extraction of specific compounds. MIPs can be customized and
modified simply by varying the selection and composition of the functional and
51

crosslinking monomers. Functional monomers may not only be selected from the ones
that are commercially available

104

, but also designed and synthesized for target

compounds, which allows the possibility of MIP being highly selective. The synthesis is
also relatively easy and inexpensive.
Compared to using only commercially available functional monomers such as
methacrylic acid (MAA), multifunctional monomers that contain more than one
functional group can bind with a higher affinity to the template molecule and with
reduced nonspecific binding to other molecules. 87 105 106

Figure 4.1 Energy-minimized model of the complex of a tris-urea scaffold and LPA 18:1.

MIPs with urea moieties as receptors for the phosphate group have been designed
and synthesized. The N-H groups of urea can bind to phosphates via hydrogen bonding
52

and electrostatic interactions.

107 108 109

However, no prior studies have been reported

involving specific LPA analysis. Figure 4.1 shows an energy-minimized model of a 1:1
complex of a tris-urea scaffold and LPA using molecular mechanics and GasteigerHückel charges.
In this study, we synthesized an MIP that could be used as the stationary phase in
an SPE cartridge. The functional monomer selected and synthesized was multifunctional,
containing three urea groups. Because of the selectivity of this MIP, interfering
phospholipids could be removed from LPA-containing samples. The elimination of the
LLE step not only improved recoveries of LPA, but also simplified and shortened the
protocol.
4.2
4.2.1

Experimental
Instruments and materials
NMR spectra were recorded on ARX-400 Advance Bruker spectrometer. FTIR

spectra were obtained on a ThermoFisher Nicolet iS10 infrared spectrometer (Thermo
Scientific, Madison, WI) in reflection geometry using a single bounce diamond
attenuated total reflectance (ATR) accessory. LPA were separated on a LunaTM C-8 (50
× 2 mm, 3 µm) column connected to a guard cartridge with 2.0 to 3.0 mm internal
diameters (Phenomenex) in an Accela UPLC system (Thermo Fisher, San Jose, CA). MS
data were collected via an LTQ-Orbitrap XL Discovery instrument (San Jose, CA, USA),
equipped with an ESI ion max source. SEM image were collected with a CEMN’s Zeiss
Sigma VP SEM.
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All phospholipids were purchased from Avanti Polar Lipids (Alabaster, AL,
USA). Hexadecylphosphonic acid, octadecylphosphonic acid, tris(2- aminoethyl) amine,
2-isocyanatoethyl methacrylate, methacrylic acid (MAA), ethylene glycol dimethacrylate
(EGDMA), and 2,2’-azobisisobutyronitrile (AIBN) were purchased from Sigma- Aldrich
(USA). EGDMA was purified by distillation in vacuo. Human plasma were collected by
Lampire Biological Laboratories Inc., from female donors, processed to obtain plateletfree plasma, and frozen at -80 ºC Empty SPE tubes and frits were purchased from SigmaAldrich (USA). HPLC grade methanol, chloroform and water were purchased from VWR
(USA).
4.2.2

Synthesis of monomer 1.
2-Propenoic acid, 2-methyl-, 18-methyl-8-[2-[[[[2-[(2-methyl-1-oxo-2-propen-

1-yl)oxy]ethyl]amino]carbonyl]amino]ethyl]-4,12,17-trioxo-16-oxa-3,5,8,11,13pentaazanonadec-18-en-1-yl ester was synthesized as described in literature110 Tris(2aminoethyl) amine (2.2 g, 15.04 mmol) was dissolved in 110 mL dichloromethane and
cooled to 0 ºC before 2-isocyanatoethyl methacrylate was added in dropwise. The
mixture was stirred at room temperature for 4 h. The solvent was evaporated and dried
under vaccum. The yield of the product was 9.2 g (100%). 1H-NMR data was in
agreement with literature. 1H NMR (400 MHz, CDCl3): δ 6.09 (s, 3H), 6.03 (bs, 3H),
5.80 (bs, 3H), 5.55 (s, 3H), 4.16 (bs, 6H), 3.43 (bs, 6H), 3.12 (bs, 6H), 2.48 (bs, 6H), 1.90
(s, 9H).

C NMR (400 MHz, CDCl3): δ 18.40, 38.72, 39.32, 55.36, 64.29, 126.06,

13

136.17, 159.45, 167.52. NMR spectra of monomer 1 are shown in Figure 4.2 and 4.3.
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Figure 4.2 1H-NMR spectrum of monomer 1.
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Figure 4.3
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C-NMR spectrum of monomer 1.
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Figure 4.4 1H-NMR spectrum of monomer 2.
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Figure 4.5

13

C-NMR spectrum of monomer

4.2.3

Synthesis of monomer 2
1,1'-(1,3-phenylenebis(methylene))bis(3-(4-vinylphenyl)urea) was synthesized

as described in literature111. A solution of 4-aminostyrene (1.19 g, 10 mmol) in anhydrous
THF (40 mL) was stirred at room temperature before 1,3-bis(isocyanatemethyl)benzene
(0.78 mL, 5 mmol) was added under N2. The reaction was stirred overnight to form a
white precipitate. The precipitate was filtered and dried under vacuum to afford the
product (1.62 g, 76.1%). 1H-NMR (400 MHz, [d6] DMSO): δ 4.30 (d, 4 H), 5.08 (d, 2 H),
5.67 (d, 2 H), 6.62 (dd, 4 H), 7.15–7.45 (m, 12 H), 8.62 ppm (s, 2 H).

13

C-NMR (400

MHz, [d6] DMSO): δ 42.75, 111.54, 117.58, 125.63, 125.93, 126.59, 128.33, 130.13,
136.33, 140.26, 140.38, 155.03. NMR spectra of monomer 2 are shown in Figure 4.4 and
4.5.
4.2.4

Synthesis of monomer 3 and 4.
Vinyl-benzyl-cyclen monomer and Zn (II) vinyl-benzyl-cyclen monomer were

synthesized as described in literature112.
1,4,7-tris(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane.

Di-tert-

butyl-dicarbonate (3.59g, 16.43 mmol) solution in CHCl3 (50 mL) was added dropwise to
the solution of cyclen (1.0 g, 5.80 mmol) and triethylamine(1.81 g, 17.88 mmol) in
CHCl3 (60 mL) over a 3 hour period. The reaction was stirred for 24 h at rt before the
solvent was removed under reduced pressure. The crude product was purified via column
chromatography using silica gel to afford 1,4,7-Tris(tert-butyloxycarbonyl)-1,4,7,10tetraazacyclododecane as a colorless solid (1.92 g, 70.1%).
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1-(4-vinylbenzyl)-4,7,10-tris(tert-butyloxycarbonyl)-1,4,7,10tetraazacyclododecane.

A solution

of 1,4,7-Tris(tert-butyloxycarbonyl)-1,4,7,10-

tetraazacyclo- dodecane (1.7 g, 3.60 mmol), K2CO3 (0.75 g, 5.4 mmol), KI (0.60 g, 3.6
mmol) , and 4-vinylbenzene chloride (0.82 g, 5.40 mol) in MeCN (60 mL) was stirred at
70 ºC for 3 h. After the insoluble inorganic salts were removed by filtration, the solvent
of the filtrate was evaporated under reduced pressure. The crude product was purified by
column chromatography to provide 1-(4-vinylbenzyl)-4,7,10- tris(tert - butyloxycarbonyl)
-1,4,7,10-tetraazacyclododecane (1.56 g, 73.6%).
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt. Trifluoroacetic
acid (12.78 g, 112.1 mmol) is added dropwise to the solution of 1-(4-vinylbenzyl)-4,7,10tris(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane (1.20 g,

2.04 mmol) in

CH2Cl2 (130 mL) at 0 ºC. The reaction is stirred overnight at rt. The solvent was
evaporated under reduced pressure before toluene (10 mL) was added to the residue and
evaporated under reduced pressure. The residue was recrystallized from Et2O-EtOH to
afford 1-(4-Vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt (0.98 g, 93.4 %).
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane.

A

solution

of

1-(4-

vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt (0.8g, 1.55 mmol) in water was
added to 1M NaOH solution. The aqueous solution was extracted with CHCl3 (50 mL ×
5) and the organic layers were combined and dried over anhydrous Na2SO4. The solvent
was

evaporated

under

reduced

pressure

to

afford

1-(4-vinylbenzyl)-1,4,7,10-

tetraazacyclododecane (0.44 g, 98.4 %) 1H NMR (400 MHz, CDCl3): δ 0.40-0.80 (m, 16
H), 1.62 (s, 2H), 3.25 (d, 1H), 3.79 (d, 1H), 4.76 (dd, 1H), 5.30 (d, 2H), 5.44 (d, 2H). 13C
60

NMR (400 MHz, CDCl3): δ 43.69, 44.84, 45.68, 50.28, 57.80, 51.98, 113.46, 125.99,
129.53, 136.23, 136.36, 138.52. NMR spectra of monomer 3 are shown in Figure 4.6 and
4.7.
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane

Zn(NO3)2

salt,

[ZnL2(NO3)2]. A solution of Zn(NO3)2· 6H2O (0.23 g) in EtOH (4 mL) was added to a
solution of 1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane (0.20 g, 0.70 mmol) in
EtOH (0.3 mL) at 60 ºC and stirred for 1 h. The solvent was evaporated under reduced
pressure and the residue was recrystallized from EtOH-H2O to afford 1-(4-vinylbenzyl)1,4,7,10-tetraazacyclododecane Zn (NO3)2 salt, [ZnL2(NO3)2]. (0.23 g, 69.7 %) 1H NMR
(400 MHz, CDCl3): δ 0.30-1.1 (m, 16 H), 1.80 (s, 2H), 3.19 (d, 1H), 3.73 (d, 1H), 4.62
(dd, 1H), 5.17 (d, 2H), 5.34 (d, 2H). 13C NMR (400 MHz, CDCl3): δ 41.69, 41.81, 43.26,
44.03, 44.15, 48.64, 54.85, 114.47, 125.94, 130.62, 131.22, 135.71, 137.45. NMR spectra
of monomer 4 are shown in Figure 4.8 and 4.9.
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Figure 4.6 1H-NMR spectrum of monomer 3.
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Figure 4.7
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C-NMR spectrum of monomer 3.
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Figure 4.8 1H-NMR spectrum of monomer 4.
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Figure 4.9
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C-NMR spectrum of monomer 4.

4.2.5

Preparation of imprinted polymer and non-imprinted polymer
Octadecylphosphonic acid (1.00 g, 2.99 mmol), monomer 1 (1.83 g, 2.99 mmol)

and methacrylic acid (0.257 g, 2.99 mmol) were dissolved in 37 mL chloroform and
allowed to stand for 60 min for complex formation. EGDMA (11.9 g, 59.8 mmol) was
added to the mixture in one portion. The mixture was purged by bubbling nitrogen for 5
min before and after AIBN (0.245g, 1.49 mmol) was added. Polymerization was carried
at 55 ºC for 16 h. Polymers were crushed into small pieces before washing with MeOH,
and extracted using a Soxhlet apparatus with MeOH for 48 h, before grinding and sieving
to 63-90 µm.
A non-imprinted polymer was synthesized using the same protocol, but without
the presence of the template octadecylphosphonic acid.
4.2.6

1

H NMR titrations

Stock solutions of monomer 1 (40 mM) and octadecylphosphonic acid (20 mM)
were prepared in CDCl3. The initial concentration of template was 5 mM and kept
constant. The monomer concentration was 0, 0.5, 1, 1.5, 2, 3, 4, 5, 7.5, 10, 15 mM,
respectively. The chemical shifts of proton in urea group and the adjacent methylene
group were monitored. Titration of methacrylic acid and template octadecylphosphonic
acid were performed using the same protocol.
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4.2.7

Job plots for monomers with template
Stock solutions of functional monomers and templates were the same as in the 1H-

NMR titration experiment. The concentration of the solution was 10 mM and the mole
ratio of template and monomer were varied from 0/10 to 9/1. The chemical shifts of the
proton of the urea group and the adjacent methylene group were monitored. A titration of
the methacrylic acid and octadecylphosphonic acid was performed using the same
protocol.
4.2.8

LPA enrichment procedure with MIP
600 µL human plasma was mixed with 2 mL MeOH-CHCl3 2:1, vortexed at 2000

rpm for 30 s and incubated at 4 ºC for 20 min. After warming to rt, the mixture was
centrifuged at 2000 rpm for 10 min. The supernatant was decanted and loaded onto a
cartridge packed with the non-imprinted polymer (NIP). The cartridge was eluted with 2
mL 0.05% NH4OH in MeOH. The eluent was acidified to pH 3.0 with concentrated
formic acid and loaded to a cartridge packed with 30 mg MIP. The cartridge was washed
with 2 mL CHCl3, followed by 2 mL MeOH. LPAs were eluted with 3 mL 0.05%
NH4OH in MeOH. The solvent was evaporated under N2 stream and the residue was
reconstituted in 0.2 mL MeOH-H2O 9:1.
4.2.9

LC-ESI/MS procedure for plasma analysis
Samples (10 µL) after the enrichment with SPE step were injected to a Luna C-8

(50 × 2 mm, 3 µm) column at 40 ºC. The mobile phase, MeOH–HCOOH (pH 2.5) 9:1,
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was delivered at a flow rate of 0.6 mL/min. Ions were created in negative ion mode by
setting the sprayer voltage at 3.0 kV and the capillary temperature at 300 ºC.
4.2.10 Swelling of polymers
Dry polymer was placed in a 10 mL graduated cylinder and weighed. The weight
and volume of the dry polymer were used to calculate the density of the polymer. Excess
CHCl3 was added and air bubbles removed by stirring. The polymer was allowed to swell
for 24 h. The swelling factor was calculated as the ratio of the volume of the swollen
polymers to the dry polymers.
4.3
4.3.1

Results and discussion
Monomer selection and synthesis
Functional monomers and crosslinking monomers were selected from a virtual

library of 22 functional monomers containing functionalities for phosphate binding and 7
crosslinking monomers. A Leapfrog algorithm from Tripos Inc. was used to determine
the binding of the functional monomer candidates and target analyte LPA 18:0.
Functional monomers with the highest binding score and crosslinking monomers with the
lowest binding score were selected as the best candidates for polymer preparation.
Selected functional monomers 1-5 are shown in Figure 4.10.

Monomer 1-4 are

synthesized following the protocols in literature. The synthesis schemes are shown in
Scheme 4.1-4.3.
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Figure 4.10 Chemical structures of selected functional monomers.

Scheme 4.1 Synthesis of monomer 1.
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4.3.2

Characterization of monomer binding properties
To study the binding properties of monomer 1, octadecylphosphonic acid was

used as the anionic guest. Octadecylphosphonic acid was also selected as the template for
imprinting instead of LPA, to avoid interfering from potential LPA residue after template
extraction. Weakly polar aprotic solvent chloroform was used as the solvent to avoid
hydrogen bonding between the solvent and the template or the monomers. Data and 1H70

NMR spectra of the Job plot are shown in Table 4.1 and Figure 4.11. The binding affinity
of the urea functional group to the phosphate group was monitored using 1H NMR.
Downfield chemical shift of the urea N-H group and adjacent methylene protons were
observed and monitored. Based on the results from Job plots, the maximum chemical
shift was obtained when the mole ratio of monomer and guest was 1:1. Job plot is shown
in Figure 4.12.
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Table 4.1 Data for the Job plot performed by 1H NMR titration in CDCl3.
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Mixture
No.

Monomer 1 (mM)

Template (mM)

Mole fraction (monomer 1)

δ (ppm)

∆δ (ppm)

∆δ × Mole fraction

1

10

0

1

3.1683

0.0000

0.0000

2

9

1

0.9

3.1901

2.1683

0.0196

3

8

2

0.8

3.2291

2.1901

0.0486

4

7

3

0.7

3.2784

2.2291

0.0770

5

6

4

0.6

3.3346

2.2784

0.0998

6

5

5

0.5

3.4273

2.3346

0.1295

7

4

6

0.4

3.4633

2.4273

0.1180

8

3

7

0.3

3.5123

2.4633

0.1032

9

2

8

0.2

3.5538

2.5123

0.0771

10

1

9

0.1

3.5563

2.5538

0.0388

11

0

10

0

-

-

-
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Figure 4.11 1H NMR spectra of Job plot data for trisurea and octadecylphosphonic acid. Each spectrum is labeled with the mixture
numbers in Table 3.1.

Figure 4.12 Job plot of monomer 1 with octadecylphosphonic acid in CDCl3 showing a
maximum at 0.5 mole fraction of trisurea.

The 1H NMR titration experiment in CDCl3 was carried out to determine the
association constant of monomer 1 and octadecylphosphonic acid. Data and results are
shown in Table 4.2 and Figure 4.13.

1

H NMR titration of monomer 1 using

octadecylphosphonic acid as the guest is shonw in Figure 4.14. The association constant
K is calculated to be 83.17 M-1.
Job plot and NMR titration experiments were also done using monomer
methacrylic acid as the host and octadecylphosphonic acid as the guest. No chemical shift
was observed for the proton in N-H group or the adjacent methylene groups.
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Table 4.2 Data of 1H NMR titration of monomer 1 with template in CDCl3.
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Mixture No.

Monomer 1 (mM)

Template (mM)

∆δ (ppm)

∆δ (ppm)

∆δ (ppm)

1

5

0

0

0

0

2

5

0.5

0.12

0.02

0.06

3

5

1

0.19

0.04

0.1

4

5

1.5

0.26

0.07

0.16

5

5

2

0.33

0.09

0.2

6

5

3

0.46

0.13

0.29

7

5

4

0.6

0.17

0.38

8

5

5

0.64

0.21

0.47

9

5

7.5

0.66

0.29

0.64

10

5

10

0.33

0.74

11

5

15

0.37

0.84
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Figure 4.13 1H NMR titration spectra of trisurea and octadecylphosphonic acid. Each spectrum is labeled with the mixture number in Table 3.2.

Figure 4.14 1H NMR titration of monomer 1 using octadecylphosphonic acid as the guest.

4.3.3

Infrared spectroscopy of MIP
Fourier transform infrared spectroscopy (FTIR) spectra of the non-imprinted

polymer and imprinted polymer after template removal were collected and shown in
Figure 4.15. IR of non-imprinted polymer, 3547, 3377, 2961, 1713, 1547, 1445, 1382,
1236, 1126, 1039, 938, 841, 806, 745 cm-1. IR of imprinted polymer after template
removal, 3531, 3375, 2943, 1714, 1632, 1551, 1448, 1384, 1242, 1137, 1043, 943, 845,
784, 748 cm-1. No phosphate group peaks were observed in the spectrum of imprinted
polymer, because 95 % of the octadecylphosphonic acid was removed in the template
extraction step.
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Figure 4.15 IR spectra of (a) non-imprinted polymer and (b) imprinted polymer after template
removal.

4.3.4

SEM microphotographs of polymers
A scanning electron microscope (SEM) microphotographs in Figure 4.16 show

that both non-imprinted and imprinted polymers obtained from bulk polymerization are
irregular shaped particles.
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(a)

(b)
Figure 4.16 SEM microphotographs of non-imprinted (a) and imprinted (b) polymers.
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4.3.5

Swelling of polymers
Swelling factors and density of MIP and NIP are shown in Table 4.3.
Table 4.3 Swelling factor and density of non-imprinted and imprinted polymers.
Non-imprinted polymer

Imprinted polymer

Density

0.331 g/mL

0.647 g/mL

Swelling factor

2.05

3.47

Monomer 1 was firstly synthesized and used as the functional monomer in the
MIP preparation. Optimization of the formulations was carried out after promising
screening results were obtained. MIP with monomer 2 was also prepared and screened.
The binding of LPA to the polymer was also quite strong, necessitating further study.
MIP with monomer 4 as the functional monomer was not prepared because the complex
formed by this monomer and the template octadecylphosphonic acid could not be
dissolved in any aprotic solvent.
4.3.6

Formulation optimization of MIP
Other functional monomers including 2-vinylpyridine, 4-vinylpyridine (4-VP),

and 1-allylthiourea were also evaluated for LPA binding. However, the template OPA did
not dissolve completely in CHCl3 at the desired concentration; and the addition of the
functional monomer did not help to dissolve the template under the conditions used for
template-monomer complex formation. A bulk polymerization procedure was chosen.
Soxhlet extraction of the polymer pieces removed 95 % of the template from the
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imprinted polymer. An optimal MIP should afford high recovery and high selectivity for
LPA.
A series of MIPs formulations were prepared as shown in Table 4.4. The first
formulation attempted (Table 4.4, entry 1) included only monomer 1 as the functional
monomer. Screening results for this formulation showed that 60-80% of each individual
LPA could be recovered, but 70-80% of PA was bound to the polymer and co-eluted with
LPA from the MIP. Because of the high cross-reactivity observed between PA and LPA,
a second monomer was included in the formulation. For this purpose, methacrylic acid
(MAA) and 4-vinylpyridine (4-VP) were used in order to increase non-covalent
interactions via hydrogen bonding.
In the presence of MAA in the formulation, (Table 4.4, entry 2) the recovery of
PA was lowered by 50% due to the absence of the hydroxyl group in the PA structure.
The recovery of LPA was also increased to 70-115 %. The formulation containing, 4-VP,
(Table 4.4, entry 3) as the second monomer, showed a similar LPA recovery to the
second formulation, but with less selectivity. Thus, the second formulation (Table 4.4,
entry 2) was found to have the best required properties for the purpose of this study. A
comparison of percent recoveries of LPA and possible interferences in preliminary
screening experiments with all three formulations of MIP are shown in Figure 4.18.
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Figure 4.17 Structures of OPA, MAA, 4-vinylpyridine, EGDMA and AIBN.
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Table 4.4 Formulations of MIP and NIP.

Entry

Polymer

Template

Functional
monomer 1

Functional
monomer 2

Crosslinking
monomer

Initiator

Solvent

NIP-1

－

Monomer 1
(0.81 M)

－

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

MIP-1

OPA
(0.81 M)

Monomer 1
(0.81 M)

－

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

NIP-2

－

Monomer 1
(0.81 M)

MAA (0.81 M)

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

MIP-2

OPA
(0.81 M)

Monomer 1
(0.81 M)

MAA (0.81 M)

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

NIP-3

－

Monomer 1
(0.81 M)

4-VP (0.81 M)

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

MIP-3

OPA
(0.81 M)

Monomer 1
(0.81 M)

4-VP (0.81 M)

EGDMA
(16.2 M)

AIBN
(0.41 M)

CHCl3

1

2
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2

3

Structures of OPA, MAA, 4-vinylpyridine, EGDMA and AIBN are shown in Figure 4.17.
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Figure 4.18 Percent recoveries of LPA and possible interferences in preliminary screening experiments of three formulations of MIP.

4.3.7

SPE protocol optimization
The MIP showed a good binding affinity with LPA in organic media. About 75 %

of each LPA subspecies were bound to MIP in a CHCl3-MeOH mixture. Formic acid was
added to protonate LPA, and increased the binding to 95 %. MeOH or CHCl3 alone
could only elute 60-70% of the bound LPA from the MIP. However, more than 90 % of
the LPA could be eluted with 0.05% NH4OH in MeOH. CHCl3 followed by MeOH was
used in the washing step for the removal of neutral phospholipids, such as LPC, PC, etc.
Using CHCl3 in the washing removed only 50 % LPC; MeOH removed the remainder.
From the evaluation results, we noticed that the non-imprinted polymer showed a
stronger binding property to PA than the imprinted polymer under the same loading and
elution conditions. About 80% of the PA was retained in the non-imprinted polymer
(NIP-2), compared to 50% in the imprinted polymer (MIP-2) when samples were loaded
in 0.05% HCOOH in CHCl3 and eluted in 0.05% NH4OH in MeOH. This can be
interpreted as arising from the differences in selectivity between the non-imprinted and
imprinted polymers. The non-imprinted polymer has no selectivity in its binding to
phosphate head groups, while the imprinted polymer contains cavities that are specific
shaped for LPA molecules. This imprinting effect allows us to use the non-imprinted
polymer to retain PA before the sample was loaded to the imprinted polymer. On the
other hand, LPA was not retained in the non-imprinted polymer because of less nonspecific interaction with the polymer compare to PA, which has (double) fatty acid chains.
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4.3.8

LPA extraction and quantification in plasma
Mixtures of LPA 14:0, LPA 20:4, LPA 16:0, LPA 18:1 and LPA 18:0 with

concentrations ranging from 0.5-10 µM were evaluated with non-natural LPA 17:0 as an
internal standard. All LPAs showed linear responses in this range. Statistical values from
calibration curves are shown in Table 4.5. Calibration curves of LPA species are shown
in Figure 4.19. For all LPA species, acceptable correlation factors (R2) were obtained.
The limit of detection (LOD) was determined as the amount of analyte that corresponds
to three times the signal of the background noise.
Table 4.5 Statistical values from calibration curves for LPA species using LC/MS as the
quantification method.
LPA species

Retention time (min)

Equation

R2

LOD (µM)

14:0

3.78

y = 0.0804x + 0.0164

0.9958

0.126

20:4

4.41

y = 0.0939x + 0.0219

0.9941

0.153

16:0

4.87

y = 0.0821x + 0.0156

0.9972

0.166

18:1

5.32

y = 0.0775x + 0.0156

0.9954

0.182

18:0

6.60

y = 0.0734x + 0.0114

0.9967

0.225
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Figure 4.19 Calibration curves of LPA subspecies with LC/MS as the quantification
method. The area ratio is the peak area of individual LPA divided by the peak area of the
internal standard (LPA 17:0). Data points represent the average of 3 runs.

The recoveries of LPA were determined using LPA control samples and the
results are summarized in Table 4.6. Hexadecylphosphonic acid (5 µM) was used as an
internal standard instead of octadecylphosphonic acid to eliminate the potential interfere
from the residue of template in MIP. Two concentration LPA mixtures including 0.5 µM
and 2.5 µM were evaluated for three times.
Table 4.6 Recoveries of individual LPA species after SPE. (n = 3)
LPA species

Recovery (%)

σ

14:0

87.1

1.5

20:4

86.2

1.6

16:0

89.5

1.4

18:1

87.6

1.5

17:0

85.1

1.6

18:0

87.3

1.3
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Plasma samples and plasma samples spiked with 0.5 µM, 1 µM and 2 µM of each LPA subspecies were used to evaluate the
method and determine potential matrix interferences. All samples were prepared and analyzed in triplicates. Results of non-spiked
plasma samples and spiked samples are summarized in Table 4.7. Representative HPLC traces of plasma sample and LPA control
sample are shown in Figure 4.20.
Table 4.7 Results for LPA analysis in human plasma using LC-ESI/MS.
LPA species

Spiked with 0.5 µM

Non-spiked

Spiked with 1 µM

Spiked with 2 µM

88
average

σ

average

σ

% recovery

average

σ

% recovery

average

σ

% recovery

14:0

0.25

0.02

0.70

0.03

91.23

1.19

0.03

94.59

2.16

0.04

95.83

20:4

0.23

0.02

0.74

0.01

103.10

1.25

0.06

101.84

2.26

0.02

101.44

16:0

0.37

0.02

0.93

0.04

111.56

1.42

0.05

105.17

2.45

0.03

103.98

18:1

0.26

0.03

0.78

0.03

103.24

1.29

0.04

103.28

2.30

0.04

101.91

18:0

0.34

0.01

0.87

0.02

106.34

1.36

0.05

101.70

2.39

0.22

102.62

Total LPA

1.45

0.05

4.02

0.07

103.09

6.51

0.10

101.32

11.56

0.23

101.16
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Figure 4.20 LC-ESI/MS traces. (a) A 10 uM standard mixtures of LPAs. (b) Plasma sample. Column: Luna TM C-8 (50 × 2 mm, 3 µm) at 40 ºC.
Injection volume: 10 µL. Mobile phase: 9:1 MeOH–HCOOH (pH 2.5). Flow rate: 0.6 mL/min. Ions were detected in negative ion mode.
Sprayer voltage: 3.0 kV and Capillary temperature at 300 ºC

To determine the existence of non-LPA phospholipids in the plasma extraction
after SPE with NIP and MIP, an LC/MS full scan in negative and positive modes was
used. A mixture of phospholipids was used as the control sample and confirmed to be
detectable in either negative or positive mode. The plasma sample after extraction was
tested using the same method. Signals were compared to the LIPID MAPS Structure
Database (LMSD)64. No interfering phospholipids except traces amount of LPC could be
detected. Using the presence of LPC 15:0 as the internal standard, the concentration of
LPC 16:0, LPC 18:1 and LPC 18:0 were estimated to be 0.05 µM, 0.01 µM and 0.02 µM,
respectively. The level represents less than 0.1 % of the total physiological LPC in human
plasma.73 This result is comparable to our previous method 70.
4.4

Conclusion
The MIP prepared using monomer 1 and methacrylic acid as functional

monomers showed significant advantages for LPA extraction and enrichment in
selectivity. Using this MIP as an SPE cartridge stationary phase allows fast and simple
extraction of LPA from human plasma with high recoveries and high purities. Compared
to the previous extraction method we developed70, the current method is faster and less
labor intensive, because most of the vortexing and centrifugation steps in liquid-liquid
extraction are replaced. The extraction and quantification of plasma LPA can be
automated easily because of the elimination of liquid-liquid extraction.
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Chapter 5

5.1

Future Work

Optimization of current formulations of MIP
Synthesize MIPs with a more optimized formulation (e.g., stoichiometries of
monomers) to remove PA completely without passing the sample through the extra
SPE filled with NIP. This may be realized by adding more hydrophobic crosslinking
monomer to retain PA that contains double fatty chains. We could also attempt by
modify the ratio of functional monomers and crosslinking monomers in the
formulation.

5.2

MIP with other functional monomers
Synthesize and evaluate MIPs with other functional monomers, such as
monomers 2-5 in Chapter 4. MIPs with other functional monomers could possibly
be more advantageous for simplifying LPA extraction. For example, MIPs that could
be used in aqueous media could enable bypassing bypassing treatment with MeOH
and CHCl3. In other words, the plasma could potentially be passed directly through a
MIP cartridge if the MIP effectively binds LPA in water. To date, a MIP with 1vinylimidazole as the functional monomer showed good binding affinity to LPA
(>90 % LPA bound; however, elution was problematic) according to preliminary
screening results.

5.3

MIP for specific LPA subspecies
The MIP we are currently using is selective for LPA over other
phospholipids, but is not selective for individual LPA species. The synthesis of MIPs
91

for each individual LPA can eliminate separation with HPLC, which will simplify
and shorten the analysis. Individual subspecies quantification could also be
accomplished directly with fluorescence.
5.4

Molecularly imprinted membrane (MIM) for LPA analysis
Along with MIPs, we can also synthesize MIMs for selective LPA analysis.
Plasma LPA extractions with MIM as a filter could be advantageous because of the
potentially shorter retention time of LPA in the material. Functional monomers,
described herein could also be used as a starting point for creating LPA-selective
MIMs.

5.5

MIPs with fluorescent probes
MIPs that contain fluorescence probes within their interior could allow for
the direct determination of LPA in plasma via an optical signal. Fluorescence probes
that have been synthesized specifically for LPA detection in our research group can
be modified with vinyl groups and be incorporated during polymerization.
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